How American medicine profits from despair

American health care is expensive because it is built to be expensive

The first uncomfortable truth is that the United States does not spend more on health care because Americans go to the doctor all day for fun. The country spends more largely because prices are higher, administration is thicker, and middlemen are more powerful. That means the cost problem is not mainly about over-loving health care. It is about paying luxury prices for a system that still leaves many people lost in the parking lot.

Hospitals, outpatient care, physician services, and drug spending all cost more in the U.S. than in peer countries. Administrative overhead is also dramatically higher. So patients are not only paying for care; they are paying for billing departments, coding departments, insurer negotiations, utilization reviews, appeals, disputes, collection systems, and the glorious paperwork Olympics that makes every simple medical interaction feel like a tax audit conducted in a waiting room.

High prices hide behind complexity

One reason the system keeps winning is that most patients do not know the real price of care until after they receive it. Even with transparency rules, health care pricing is still murky enough to make a casino blush. A hospital may list one price, negotiate another with insurers, bill a facility fee on top of the physician fee, and leave the patient sorting through jargon that reads like a ransom note written by accountants.

That opacity matters. In ordinary markets, a bad price scares customers away. In medicine, the customer often shows up in pain, under stress, or in an emergency. A patient having chest pain is not going to open fifteen browser tabs and whisper, “Let’s benchmark these troponin tests.” American medicine knows this. The system’s most profitable moments often arrive when normal consumer behavior is impossible.

Despair is most profitable when care is urgent

Illness strips people of leverage. Nobody negotiates well while scared. A parent with a feverish child, an adult who thinks they may be having a stroke, or a worker trying to hold onto insurance while managing a chronic disease is not operating from a position of strength. That is exactly when high prices, out-of-network games, and surprise administrative barriers do their best work.

The No Surprises Act reduced some of the nastiest surprise-billing practices, especially around emergency care. That was real progress. But the law did not erase the deeper business logic of the system. It mostly moved part of the fight behind the curtain, where providers and insurers now duel through a federal dispute process. Patients may be shielded from some direct shocks, yet the larger pricing machine keeps humming, and those costs still echo back through premiums, network design, and future bills.

Medical debt is not a side effect. It is part of the model.

Medical debt is often described like bad weather: unfortunate, unavoidable, and somehow nobody’s fault. That framing is nonsense. Debt is the foreseeable result of charging people too much, too unpredictably, during moments when they have the fewest options. If millions of people can do everything right, have insurance, follow doctor’s orders, and still end up in collections, that is not a consumer failure. That is a business design.

In the United States, one illness can become a multi-year financial event. A surgery becomes a payment plan. An ER visit becomes a credit card balance. A mental health crisis becomes a stack of statements nobody fully understands. A diagnostic scan becomes that thing a family is still paying off long after the body has healed. The debt lingers because it is not just tied to sickness. It is tied to how the market extracts payment from distress.

Mental health and addiction care reveal the system at its most cynical

If you want to see how American medicine profits from despair in its purest form, look at mental health and addiction care. Demand is enormous. Supply is thin. Networks are often inadequate. Reimbursement can be low. Cash-pay options are widespread. And patients are frequently in no condition to navigate a labyrinth of “call this number,” “that clinician is inactive,” or “we are not accepting new patients.”

This creates a brutal split-screen reality. On one side, people cannot find affordable, in-network behavioral health care. On the other, certain segments of mental health and addiction treatment have become attractive investment targets precisely because need is so high and supply is so constrained. When access is scarce and desperation is common, pricing power gets stronger. That is not a bug. That is the business opportunity.

The therapy shortage becomes a profit center

Patients with anxiety, depression, trauma, or substance use disorder are often told help is available. In theory, that is true. In practice, many provider directories are inaccurate, many listed clinicians are unavailable, and many people hit a wall of waitlists, ghost listings, and cash-pay demands. The care technically exists in the same way a lifeboat technically exists if it is locked in a warehouse three miles away.

Private equity has recognized that behavioral health is fragmented and growing, which makes it ripe for consolidation. Investors can buy practices, expand locations, standardize operations, increase prices, chase higher-paying patients, and exit later. That can bring capital and scale. It can also bend care toward short-term returns, heavier utilization, selective service lines, and narrower patience for less profitable patients. In other words, the market enters the room and immediately asks not, “Who needs help most?” but “Which suffering has the best margin?”

Addiction treatment sits at the crossroads of need and monetization

Addiction care reveals a similar tension. The opioid crisis and broader substance use emergency created intense demand for treatment. Yet access remains uneven, medication treatment is still underused, and reimbursement rules plus network shortages keep many people on the outside looking in. At the same time, the treatment market itself has drawn investors, operators, marketers, and intermediaries eager to scale what can be billed.

None of this means every behavioral health company is exploitative or every investor is predatory. It means the economic structure rewards growth where there is pain, and American medicine has become very good at finding pain that can be organized, branded, and invoiced.

The middlemen are not exactly helping

To understand why patients keep paying so much, you have to follow the middlemen. Pharmacy benefit managers, insurers, hospital systems, revenue-cycle firms, and third-party administrators all take a turn at the wheel. Each claims to be reducing costs. Somehow the bill still arrives looking like it trained for this moment.

PBMs and the rebate funhouse

Pharmacy benefit managers were supposed to negotiate lower drug costs. In reality, the rebate system has often rewarded higher list prices and more convoluted formulary games. When pricing is driven by back-end rebates rather than straightforward lower prices at the pharmacy counter, patients with deductibles or coinsurance can get clobbered. The savings may exist somewhere in the plumbing, but they do not always show up where a human being is standing with a prescription in hand.

This is why some of the most maddening drug-pricing stories in America sound upside down: lower-cost options may exist, yet patients still encounter higher-priced versions with better formulary treatment. That is not an accident. It is what happens when the system optimizes for negotiated rebates and contractual leverage instead of simple affordability.

Prior authorization: the bureaucratic tollbooth

Then there is prior authorization, one of the most elegant ways to profit from despair without ever sending a fruit basket. In theory, prior auth prevents unnecessary care. In practice, it often delays necessary care, burns staff time, exhausts physicians, and dares sick people to give up first. That surrender is not incidental. It saves somebody money.

Think about the emotional economics here. The patient is tired, symptomatic, worried about work, and already paying premiums. Then comes the denial, the resubmission, the phone tree, the fax machine apparently maintained by an archaeology department, and the appeal. Some people persist. Many cannot. Every abandoned treatment is a small administrative victory for the payer and a deeply human loss for the patient.

Nonprofit hospitals and moral branding

One of the strangest features of American medicine is how often nonprofit status coexists with aggressive billing behavior. The public hears “nonprofit hospital” and imagines community mission, charity care, and civic obligation. Patients sometimes discover a less poetic reality: lawsuits, collections, confusing financial assistance policies, and billing practices that do not feel especially saintly.

Hospitals will argue, often correctly, that they face labor costs, capital costs, regulatory burdens, and underpayment from public programs. All true. But those pressures do not magically excuse a business model that can leave patients buried in debt while the institution expands, consolidates, advertises, and negotiates from a position of regional market power. Mission statements do not erase markups.

Consolidation makes “take it or leave it” easier

As hospitals and physician groups consolidate, competition weakens. When a health system dominates a region, insurers have less leverage, prices rise, and patients get fewer meaningful alternatives. The economic result is predictable: higher negotiated rates, stronger facility fees, and less pressure to simplify anything for the person receiving the bill. The market becomes less of a market and more of a shrug with a logo.

Why despair remains such a good business strategy

American medicine profits from despair because despair is sticky. Once a patient is scared enough, tired enough, or sick enough, they stop behaving like an empowered shopper and start behaving like a human being in trouble. The system knows this. Every layer of opacity, every narrow network, every prior-auth delay, every inflated list price, every inaccurate provider directory, and every collection notice works better when the patient has less bandwidth.

The U.S. system also separates responsibility so efficiently that accountability evaporates. The hospital blames the insurer. The insurer blames the provider. The PBM blames the manufacturer. The employer blames the market. The regulator blames statutory limits. Meanwhile the patient, who never asked to become a part-time claims specialist, is left holding the only truly integrated document in the entire system: the bill.

And that is why reform is so difficult. Too many organizations earn revenue from the very confusion and urgency that reform would reduce. A system built on complexity will fight simplification the way a raccoon fights the loss of a shiny object. Loudly, unpredictably, and with surprising dexterity.

What a less predatory system would look like

A better system would not just cap a few prices and call it a day. It would make care understandable before people receive it. It would force cleaner pricing, stronger network adequacy, easier access to behavioral health, real enforcement against deceptive billing, and fewer opportunities for middlemen to profit from opacity. It would also judge success less by how cleverly institutions maximize revenue and more by whether patients can get treated without becoming financially haunted.

That means making drug pricing simpler, not merely differently complicated. It means shrinking prior authorization where it delays clinically necessary care. It means holding provider directories to reality, not fantasy. It means watching private equity and consolidation with something stronger than polite concern. And it means treating medical debt as evidence of system failure, not a character test for patients.

American medicine is full of skilled, decent people doing hard work. The tragedy is that many of them operate inside a payment structure that monetizes fear better than it relieves it. Until that changes, the U.S. will remain a place where the sick are asked not only to heal, but also to finance the architecture of their own distress.

Experiences that show how the system turns suffering into revenue

To understand this issue emotionally, not just economically, picture the ordinary experiences that repeat across the country every day. A woman feels a lump, gets imaging, then receives three separate bills from three separate entities, none of which agree with the estimate she was given. A father with decent employer coverage rushes his son to the emergency room, only to learn later that one physician involved in the visit billed differently from the hospital. A college student finally works up the courage to seek therapy, spends hours calling names from an insurer’s directory, and discovers half the clinicians are not taking patients, do not accept that insurance, or were never truly available in the first place.

These stories are not dramatic because they are rare. They are dramatic because they are normal. In American medicine, many people do not remember their worst health care experience by the diagnosis alone. They remember the paperwork, the denial letter, the collection notice, the hold music, the explanation of benefits that explained absolutely nothing, and the weird sensation of being treated like both a patient and a billing opportunity at the same time.

Consider the person with diabetes who does everything right. They monitor their health, refill prescriptions, show up to appointments, and still get trapped between deductibles, formulary changes, and pharmacy counter sticker shock. Or the worker with chronic back pain who is told a treatment is medically appropriate, then delayed by prior authorization until the pain worsens, they miss work, and eventually land in urgent care because waiting became more expensive than treating. The system saves pennies in one office and creates chaos in three others.

Mental health care can be even more crushing because the administrative burden lands on people whose energy, concentration, or hope may already be running on fumes. Someone with severe anxiety gets asked to make ten calls, compare benefits, appeal a denial, and locate an in-network specialist in a sparse market. A person with depression receives a bill large enough to make continuing care feel irresponsible. A family trying to find addiction treatment learns there is a bed available, but not under their plan, not at that level of care, or not without paying an amount that would blow up rent, groceries, and everything else that keeps life stitched together.

Then comes the aftershock. Even when the immediate crisis passes, the financial residue stays. People cut back on food, delay dental visits, avoid follow-up appointments, stop taking medications as prescribed, or ignore new symptoms because the last encounter taught them that getting care can damage a household budget for years. In that way, despair becomes self-reinforcing. The fear of debt keeps people from seeking care, delayed care worsens illness, worse illness becomes more expensive, and the system rings the register again.

What makes these experiences especially corrosive is the moral confusion they create. Patients are told to be proactive, responsible, and health-conscious. But when they act responsibly, the system often punishes them anyway. They ask for help and receive a portal login, a coding dispute, a provider search dead end, and a payment plan. They are told health care is about compassion, then handed terms and conditions that sound like a cable contract drafted during a migraine.

That is why the phrase “profits from despair” resonates. It is not just about balance sheets. It is about the feeling that the moment you are weakest is the moment the machine becomes most efficient. The illness hurts, but the transaction changes how people see institutions, fairness, and even their own worth. Many patients walk away believing the system never truly saw them as a person in crisis. It saw them as a claim, a code, an authorization request, a negotiable rate, and finally, if necessary, a debtor.

Conclusion

American medicine does not profit from despair because doctors are uniquely greedy or patients are uniquely unlucky. It profits from despair because its incentives reward opacity, fragmentation, scarcity, and delay. The system makes money when people cannot shop, cannot wait, cannot decode the fine print, and cannot fight every denial. That is why the problem persists across hospitals, insurers, drug channels, mental health networks, and debt collection systems. Despair lowers resistance. Complexity raises revenue.

Until the structure changes, Americans will keep living inside a health care economy that performs astonishing medical feats while routinely failing the simpler test of mercy. It can transplant organs, sequence tumors, and stabilize trauma, yet still send a family into debt for being too sick, too scared, or too tired to outmaneuver the paperwork. For a country this rich, that is not just inefficient. It is morally embarrassing.